Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FGFR-IN-7 (compound 17) is an orally active, potent FGFR modulator with the ability to penetrate the blood-brain barrier. It exhibits neuroprotective properties, enhancing brain exposure and decreasing the likelihood of phospholidosis. FGFR-IN-7 proves valuable for research on neurodegenerative diseases [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | FGFR-IN-7 (compound 17) is an orally active, potent FGFR modulator with the ability to penetrate the blood-brain barrier. It exhibits neuroprotective properties, enhancing brain exposure and decreasing the likelihood of phospholidosis. FGFR-IN-7 proves valuable for research on neurodegenerative diseases [1]. |
In vivo | FGFR-IN-7 (compound 17), administered orally at a dosage of 1 mg/kg once daily for a duration of 10 days, significantly improves the recovery of coordinated movement in rats within an acute stroke model in vivo [1]. |
分子量 | 374.81 |
分子式 | C16H21ClF2N4O2 |
CAS No. | 2488764-17-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FGFR-IN-7 2488764-17-4 Inhibitor inhibitor inhibit